Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Vedolizumab 300 Mg Rec [Cogd] (CDM 4121743) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved October 9, 2026 , from http://ppman.hank.ai/transparency/procedure/4121743/by-state?code_type=CDM
“Vedolizumab 300 Mg Rec [Cogd] (CDM 4121743) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/4121743/by-state?code_type=CDM. Accessed
October 9, 2026 .
“Vedolizumab 300 Mg Rec [Cogd] (CDM 4121743) by State,” HANK Price Transparency ,
accessed October 9, 2026 ,
http://ppman.hank.ai/transparency/procedure/4121743/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
4121743 — Vedolizumab 300 Mg Rec [Cogd]
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$13,520
National median
$10,243 – $15,600
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 4121743 (CDM), with interquartile range
State Median p25 p75
TX $13,520 $10,243 $15,600